NCT00031902 is a Phase 1 clinical trial of bleomycin sulfate in Lymphoma, sponsored by Lymphoma Trials Office.

Who is sponsoring NCT00031902?

NCT00031902 is sponsored by Lymphoma Trials Office.

What drugs are being tested in NCT00031902?

Interventions in NCT00031902: bleomycin sulfate, rituximab, prednisolone, vincristine sulfate.

Is NCT00031902 still recruiting?

NCT00031902 is currently status unknown. Last updated 19 September 2013.

Last reviewed 2013-09-19 · How we verify

NCT00031902

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rituxumab Combined With Chemotherapy (PVB) For Poor Prognosis HIV-Related Non-Hodgkin's Lymphoma

Status unknown Phase 1 Last updated 19 September 2013

What this trial tests

Phase 1 trial testing bleomycin sulfate in Lymphoma. Status unknown.

Timeline

1 October 2001

Quick facts

Lead sponsor	Lymphoma Trials Office
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Primary purpose	treatment
Start date	1 October 2001
Sites	2 locations across United Kingdom

Drugs / interventions tested

bleomycin sulfate — full drug profile →
rituximab — full drug profile →
prednisolone — full drug profile →
vincristine sulfate (Vincristine Sulfate) — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Lymphoma Trials Office

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of rituximab plus combination chemotherapy in treating patients who have HIV-related non-Hodgkin's lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of bleomycin sulfate

Trials testing the same drug.

NCT01026220 — Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma · Phase 3 · completed
NCT00678327 — Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Sta · Phase 3 · completed
NCT00104676 — Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors · Phase 3 · completed
NCT00053352 — Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors · Phase 3 · completed
NCT00002565 — Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma · Phase 3 · completed

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00031902 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lymphoma Trials Office
Last refreshed: 19 September 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00031902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing